A Phase 3 interventional study of Rivaroxaban and Placebo in Heart Failure and Coronary Artery Disease, sponsored by Janssen Research & Development, LLC. Completed at 578 sites in 32 countries. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2019-05-10.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Heart Failure by Johnson & Johnson — 3 open to participants now, 5 under way, none of them phase 3. Heart Failure · Johnson & Johnson.
Among the 42 studies in Heart Failure by Johnson & Johnson, this one is the 3rd largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2013, is one of 12 in phase 3, and was the 26th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →3 of the 42 studies in Heart Failure by Johnson & Johnson are open now, in 2 countries. Recruiting first, the newest first:
Abiomed Inc. · Sites in United States
Ages 18–80
Abiomed Inc. · Sites in Germany
Ages 18+
V-Wave Ltd
Ages 18+
By country, each count listing its studies:
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 12 · Phase 4 1
First in 1996; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,081 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 91 across the 33 interventional studies, 918 across the 8 observational. Of the 31 that completed or were terminated, 11 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 42 studies in Heart Failure by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensated heart failure.
This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), parallel group (each participant group receives different treatments simultaneously), event driven (the study duration is determined by the time taken for a specific number of events to occur), multicenter study to assess the effectiveness and safety of rivaroxaban compared with placebo, in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensated heart failure. Participants will be randomly assigned in a 1:1 ratio to receive either rivaroxaban or placebo (each in addition to standard of care for heart failure and coronary artery disease as prescribed by their managing physician). The study will consist of a screening phase, a double-blind treatment phase, and a follow-up after the sponsor-announced global treatment end date (GTED, defined as the date when 1200 primary efficacy outcome events are predicted to have occurred). The double-blind treatment phase is estimated to last for 6 to 54 months. Participants will discontinue study drug after taking both their morning and evening doses on the GTED and will return to the study center for the end-of-study visit (between 15 and 45 days but no sooner than 15 days after the GTED). Patient safety will be monitored throughout the study. The average study duration for participants is expected to be approximately 29 months. The study drug, rivaroxaban, is approved in the United States and in multiple countries around the world for the prevention and treatment of a number of thrombosis-mediated conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant will receive 2.5 mg of rivaroxaban twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Drug: Rivaroxaban · Other: Standard of care for heart failure and coronary artery disease
Each participant will receive matching placebo twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Drug: Placebo · Other: Standard of care for heart failure and coronary artery disease
Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke
Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient \[pt\]-year \[yr\]) = 100\*n/(total risk exposure), where n is the number of events.
Time frame: Up to Global treatment end date (approximately 54 months)
Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability
Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
Time frame: Up to 227 Weeks
Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF)
Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
Time frame: Up to Global treatment end date (approximately 54 months)
Event Rate of Cardio Vascular Death
Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
Time frame: Up to Global treatment end date (approximately 54 months)
Event Rate of Re-Hospitalization for Worsening of Heart Failure
Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
Time frame: Up to Global treatment end date (approximately 54 months)
Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV)
Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
Time frame: Up to Global treatment end date (approximately 54 months)
Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure
Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
Time frame: Up to Global treatment end date (approximately 54 months)
Event Rate of Bleeding Events That Requiring Hospitalization
Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
Time frame: Up to 227 Weeks
Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event
Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
Time frame: Up to 227 Weeks
| Milestone | Rivaroxaban | Placebo |
|---|---|---|
| Started | 2507 | 2515 |
| Completed | 2453 | 2447 |
| Not completed | 54 | 68 |
| Withdrew: Lost to follow-up | 10 | 9 |
| Withdrew: Withdrawal by subject | 42 | 55 |
| Withdrew: Other | 2 | 4 |
Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient \[pt\]-year \[yr\]) = 100\*n/(total risk exposure), where n is the number of events.
| Event rate per 100 patient-year | Rivaroxaban | Placebo |
|---|---|---|
| Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke | 13.44 | 14.27 |
Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
| Event rate per 100 patient-year | Rivaroxaban | Placebo |
|---|---|---|
| Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF) | 23.32 | 23.46 |
Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
| Event rate per 100 patient-year | Rivaroxaban | Placebo |
|---|---|---|
| Event Rate of Cardio Vascular Death | 9.46 | 9.96 |
Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
| Event rate per 100 patient-year | Rivaroxaban | Placebo |
|---|---|---|
| Event Rate of Re-Hospitalization for Worsening of Heart Failure | 17.24 | 17.45 |
Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
| Event rate per 100 patient-year | Rivaroxaban | Placebo |
|---|---|---|
| Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV) | 13.30 | 14.04 |
Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
| Event rate per 100 patient-year | Rivaroxaban | Placebo |
|---|---|---|
| Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure | 24.84 | 24.57 |
Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
| Event rate per 100 patient-year | Rivaroxaban | Placebo |
|---|---|---|
| Fatal Bleeding | 0.22 | 0.22 |
| Critical Space Bleeding with Permanent Disability | 0.32 | 0.48 |
Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
| Event rate per 100 patient-year | Rivaroxaban | Placebo |
|---|---|---|
| Event Rate of Bleeding Events That Requiring Hospitalization | 1.52 | 1.16 |
Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.
| Event rate per 100 patient-year | Rivaroxaban | Placebo |
|---|---|---|
| Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event | 2.04 | 1.21 |
Collected over Up to 54 Months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban | 565/2,507 (22.5%) | 479/2,507 (19.1%) | 53/2,507 (2.1%) |
| Placebo | 571/2,515 (22.7%) | 451/2,515 (17.9%) | 60/2,515 (2.4%) |
| Event | Rivaroxaban | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 68/2507 | 72/2515 |
| Acute Kidney InjuryRenal and urinary disorders | 17/2507 | 28/2515 |
| SepsisInfections and infestations | 16/2507 | 7/2515 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 15/2507 | 16/2515 |
| Urinary Tract InfectionInfections and infestations | 14/2507 | 9/2515 |
| Chronic Kidney DiseaseRenal and urinary disorders | 14/2507 | 7/2515 |
| AnaemiaBlood and lymphatic system disorders | 12/2507 | 7/2515 |
| BronchitisInfections and infestations | 12/2507 | 9/2515 |
| Renal FailureRenal and urinary disorders | 12/2507 | 12/2515 |
| CholecystitisHepatobiliary disorders | 10/2507 | 5/2515 |
| Event | Rivaroxaban | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 53/2507 | 60/2515 |
| Age, Continuous(years) | Rivaroxaban | Placebo | Total |
|---|---|---|---|
| Mean | 66.5 ± 10.07 | 66.3 ± 10.27 | 66.4 ± 10.17 |
| Sex: Female, Male(Participants) | Rivaroxaban | Placebo | Total |
|---|---|---|---|
| Female | 551 | 599 | 1150 |
| Male | 1956 | 1916 | 3872 |
| Ethnicity (NIH/OMB)(Participants) | Rivaroxaban | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 309 | 300 | 609 |
| Not Hispanic or Latino | 2186 | 2203 | 4389 |
| Unknown or Not Reported | 12 | 12 | 24 |
| Race (NIH/OMB)(Participants) | Rivaroxaban | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 11 | 10 | 21 |
| Asian | 362 | 365 | 727 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 29 | 36 | 65 |
| White | 2063 | 2065 | 4128 |
| More than one race | 4 | 5 | 9 |
| Unknown or Not Reported | 36 | 34 | 70 |
| Race/Ethnicity, Customized(Participants) | Rivaroxaban | Placebo | Total |
|---|---|---|---|
| Asian | 362 | 365 | 727 |
| Black or African American | 29 | 36 | 65 |
| Other | 59 | 56 | 115 |
| White Hispanic or Latino | 258 | 251 | 509 |
| White Non-Hispanic | 1799 | 1807 | 3606 |
| Region of Enrollment(Participants) | Rivaroxaban | Placebo | Total |
|---|---|---|---|
| ARGENTINA | 76 | 76 | 152 |
| AUSTRALIA | 7 | 7 | 14 |
| BRAZIL | 80 | 80 | 160 |
| BULGARIA | 314 | 314 | 628 |
| CANADA | 14 | 14 | 28 |
| CHINA | 186 | 186 | 372 |
| CZECH REPUBLIC | 35 | 34 | 69 |
| DENMARK | 9 | 9 | 18 |
| FRANCE | 10 | 10 | 20 |
| GERMANY | 32 | 32 | 64 |
| GREECE | 8 | 8 | 16 |
| HUNGARY | 69 | 69 | 138 |
| ITALY | 35 | 36 | 71 |
| JAPAN | 133 | 132 | 265 |
| LATVIA | 12 | 13 | 25 |
| LITHUANIA | 17 | 18 | 35 |
| MALAYSIA | 17 | 17 | 34 |
| MEXICO | 73 | 73 | 146 |
| NETHERLANDS | 1 | 2 | 3 |
| POLAND | 288 | 290 | 578 |
| PORTUGAL | 20 | 22 | 42 |
| ROMANIA | 200 | 198 | 398 |
| RUSSIAN FEDERATION | 274 | 276 | 550 |
| SLOVAKIA | 41 | 41 | 82 |
| SOUTH AFRICA | 8 | 8 | 16 |
| SOUTH KOREA | 24 | 24 | 48 |
| SPAIN | 89 | 89 | 178 |
| SWEDEN | 2 | 3 | 5 |
| TURKEY | 96 | 96 | 192 |
| UKRAINE | 264 | 265 | 529 |
| UNITED KINGDOM | 13 | 12 | 25 |
| UNITED STATES | 60 | 61 | 121 |
Showing the first 100 of 578 sites across 32 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2013 to primary completion in Apr 2018, 55 months.
Results were first posted in May 2019, 1 year after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 55 months is above that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban
Janssen Research & Development, LLC →